Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard D Press

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Blood Advances|August 8, 2022
Distinguishing STAT3/STAT5B-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profilingMark Kavesh, Maedeh Mohebnasab, Marcela Riveros Angel, et al.
Blood Cancer Journal|April 23, 2023
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemiaYonghong Li, Jose Solis-Ruiz, Fei Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic responseRichard D Press, Chad Galderisi, Rui Yang, et al.
International Journal of Molecular Sciences|July 27, 2024
Evaluation of a New Closed-System Automated RT-qPCR Assay for the Rapid Detection and Monitoring of Common Nucleophosmin Mutations in Patients with Acute Myeloid LeukemiaRichard D Press, Dana Dressel, Michelle McBean, et al.
Leukemia Research Reports|September 3, 2014
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemiaKim-Hien T Dao, Magdolna B Solti, Julia E Maxson, et al.
Blood|February 10, 2006
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CMLRichard D Press, Zac Love, Ashlie A Tronnes, et al.
American Journal of Hematology|May 25, 2019
Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapseRichard D Press, Garrett Eickelberg, Allison Froman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 23, 2025
Impact of germline CHEK2 pathogenic variants on the risk of Acute Myeloid Leukemia and Myelodysplastic syndromeFei Yang, Nicola Long, Jonathan C Savage, et al.
Blood|June 4, 2010
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinibDaniel W Sherbenou, Oliver Hantschel, Ines Kaupe, et al.
The American Journal of Medicine|November 3, 2007
Biological variability of transferrin saturation and unsaturated iron-binding capacityPaul C Adams, David M Reboussin, Richard D Press, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Blood Advances|August 8, 2022
Distinguishing STAT3/STAT5B-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profilingMark Kavesh, Maedeh Mohebnasab, Marcela Riveros Angel, et al.
Blood Cancer Journal|April 23, 2023
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemiaYonghong Li, Jose Solis-Ruiz, Fei Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic responseRichard D Press, Chad Galderisi, Rui Yang, et al.
International Journal of Molecular Sciences|July 27, 2024
Evaluation of a New Closed-System Automated RT-qPCR Assay for the Rapid Detection and Monitoring of Common Nucleophosmin Mutations in Patients with Acute Myeloid LeukemiaRichard D Press, Dana Dressel, Michelle McBean, et al.
Leukemia Research Reports|September 3, 2014
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemiaKim-Hien T Dao, Magdolna B Solti, Julia E Maxson, et al.
Blood|February 10, 2006
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CMLRichard D Press, Zac Love, Ashlie A Tronnes, et al.
American Journal of Hematology|May 25, 2019
Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapseRichard D Press, Garrett Eickelberg, Allison Froman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 23, 2025
Impact of germline CHEK2 pathogenic variants on the risk of Acute Myeloid Leukemia and Myelodysplastic syndromeFei Yang, Nicola Long, Jonathan C Savage, et al.
Blood|June 4, 2010
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinibDaniel W Sherbenou, Oliver Hantschel, Ines Kaupe, et al.
The American Journal of Medicine|November 3, 2007
Biological variability of transferrin saturation and unsaturated iron-binding capacityPaul C Adams, David M Reboussin, Richard D Press, et al.
Pageof 6